8-K: Verve Therapeutics Announces Positive Pipeline Progress and Reports Year-End 2024 Financial Results

Verve Therapeutics reports pipeline advancements, including upcoming data releases for VERVE-102 and VERVE-201, and a strong cash position extending into mid-2027.

Summary

• Verve Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, targeting PCSK9, is expected in the second quarter of 2025, with final dose escalation data in the second half of 2025.
• VERVE-102 has been well-tolerated, with no treatment-related serious adverse events or clinically significant laboratory abnormalities observed.
• Delivery of an opt-in package to Eli Lilly and an opt-in decision from Lilly are expected in the second half of 2025.
• Enrollment is ongoing in the Pulse-1 Phase 1b clinical trial of VERVE-201, targeting ANGPTL3.
• The company's cash, cash equivalents, and marketable securities totaled $524.3 million, providing a cash runway into mid-2027.
• Collaboration revenue for the fourth quarter of 2024 was $13.1 million, and $32.3 million for the full year.
• R&D expenses were $55.0 million for the fourth quarter of 2024, and $204.3 million for the full year.
• Net loss was $50.0 million for the fourth quarter of 2024 and $198.7 million for the full year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the pipeline progress, strong cash position, and upcoming milestones. However, the net loss and increased R&D expenses temper the overall sentiment.

Positives

• VERVE-102 shows good tolerability in the Heart-2 Phase 1b clinical trial.
• The company has a strong cash position of $524.3 million, providing a runway into mid-2027.
• Collaboration revenue increased significantly in 2024 compared to 2023.
• Verve regained all rights to develop a novel, in vivo gene editing program for liver disease, previously part of a collaboration agreement with Vertex Pharmaceuticals.
• The company is advancing its VERVE-301 program targeting the LPA gene.

Negatives

• Verve Therapeutics reported a net loss of $50.0 million for the fourth quarter of 2024 and $198.7 million for the full year.
• R&D expenses increased in 2024 compared to 2023.

Risks

• The company's success depends on the timely submission and approval of regulatory applications for its product candidates.
• Clinical trial results may not replicate positive results from preclinical studies or earlier-stage trials.
• The company may need to raise substantial additional capital to achieve its business objectives.
• The company faces risks associated with managing expenses and protecting intellectual property rights.

Future Outlook

Verve expects to report initial data from the Heart-2 trial in the second quarter of 2025 and anticipates additional milestones in the second half of 2025, including final data from the dose escalation portion of the Heart-2 trial, delivery of the opt-in package and an opt-in decision from Lilly on the PCSK9 program, as well as a program update for VERVE-201.

Management Comments

• '2024 was a year of strong execution as we made crucial progress across our pipeline and laid the groundwork for 2025 to be a milestone-rich year for Verve,' said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics.
• Dr. Kathiresan continued, 'As we capitalize on this tremendous momentum, we want to extend our deep gratitude to our chief medical officer, Dr. Frederick Fiedorek, who has decided to retire.'

Industry Context

Verve Therapeutics is operating in the competitive field of genetic medicines for cardiovascular disease, targeting major risk factors like LDL-C, remnant cholesterol, and Lp(a). The company's focus on single-course gene editing medicines differentiates it from traditional chronic therapies.

Comparison to Industry Standards

• Companies like CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine are also developing gene editing therapies, but Verve is specifically focused on cardiovascular diseases.
• The development of VERVE-102 targeting PCSK9 is comparable to Amgen's Repatha and Sanofi/Regeneron's Praluent, which are PCSK9 inhibitors, but Verve aims for a one-time treatment rather than chronic therapy.
• Verve's approach to Lp(a) reduction with VERVE-301 is significant, as current treatments have limited impact on Lp(a) levels, addressing a major unmet need.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the pipeline progress and financial results.
• Employees may be affected by the management change.
• Patients with cardiovascular disease may benefit from the development of new genetic medicines.
• Eli Lilly is a key partner and will be impacted by the opt-in decision for the PCSK9 program.

Next Steps

• Report initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 in the second quarter of 2025.
• Deliver the opt-in package to Eli Lilly and receive an opt-in decision in the second half of 2025.
• Provide a program update for VERVE-201 in the second half of 2025.
• Present at upcoming investor events and medical meetings.

Key Dates